TCMD vs ATRC vs NVCR vs MMSI vs ABT

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus 4. 6% for Abbott Laboratories (ABT). Abbott Laboratories (ABT) offers the better valuation at 11. 0x trailing P/E (15. 4x forward), making it the more compelling value choice. Analysts rate Tactile Systems Technology, Inc. (TCMD) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Abbott Laboratories (ABT) is the cheapest at 11.

0x versus Tactile Systems Technology, Inc. at 31. 3x. On forward P/E, Merit Medical Systems, Inc. is actually cheaper at 15. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Merit Medical Systems, Inc.

(MMSI) delivered a total return of -2. 7%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: MMSI returned +209. 3% versus NVCR's +38. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

22β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 894% more volatile than ABT relative to the S&P 500. On balance sheet safety, Tactile Systems Technology, Inc. (TCMD) carries a lower debt/equity ratio of 7% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus 4. 6% for Abbott Laboratories (ABT). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to 4. 9% for Merit Medical Systems, Inc.. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABT leads at 16. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — TCMD leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Merit Medical Systems, Inc.

(MMSI) trades at 15. 1x forward P/E versus 428. 7x for AtriCure, Inc. — 413. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 95. 3% to $51. 33.

In this comparison, ABT (2.

6% yield) pays a dividend. TCMD, ATRC, NVCR, MMSI do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

22), 2. 6% yield, +166. 6% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +166. 6%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TCMD is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; MMSI is a small-cap quality compounder stock; ABT is a mid-cap deep-value stock. ABT pays a dividend while TCMD, ATRC, NVCR, MMSI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.